Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

An algorithm for chemotherapy treatment of recurrent glioma patients after temozolomide failure in the general oncology setting.

Cancer chemotherapy and pharmacology - 1 May 2011

Kyritsis Athanassios P, Levin Victor A

Abstract excerpt

PURPOSE: The standard therapy for newly diagnosed malignant gliomas comprises surgery, radiotherapy, and commonly temozolomide chemotherapy. For recurrent or progressive disease after temozolomide failure, there is no consensus and only limited options for chemotherapy. METHODS: We reviewed the English literature for phase II trials of therapies for recurrent malignant glioma conducted between January 2000 and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Angiogenesis Inhibitors
Share to Antineoplastic Agents, Alkylating

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Clinical Trials, Phase II as Topic

Share to Dacarbazine

Share to Glioma

Share to Neoplasm Recurrence, Local

Share to Temozolomide

Share to Treatment Failure

Source

Identifiers

PMID: 21442438
DOI: 10.1007/s00280-011-1617-9

Genes

MGMT

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

An algorithm for chemotherapy treatment of recurrent glioma patients after temozolomide failure in the general oncology setting.PMID 21442438Read ↗

A multifaceted review of temozolomide resistance mechanisms in glioblastoma beyond O-6-methylguanine-DNA methyltransferaseSemantic proximity Read ↗

Potential Strategies Overcoming the Temozolomide Resistance for GlioblastomaSemantic proximity Read ↗

DNA methylation remodeling in temozolomide resistant recurrent glioblastoma: comparing epigenetic dynamics in vitro and in vivoSemantic proximity Read ↗

Research progress of drug resistance mechanism of temozolomide in the treatment of glioblastomaSemantic proximity Read ↗

Evolution of DNA repair defects during malignant progression of low-grade gliomas after temozolomide treatment.Semantic proximity Read ↗

Anlotinib plus Temozolomide for Recurrent Glioma: A Single-Center, Retrospective Study of 30 casesSemantic proximity Read ↗

Molecular mechanisms of temozolomide resistance in glioblastoma multiformeSemantic proximity Read ↗

Toward an effective strategy in glioblastoma treatment. Part I: resistance mechanisms and strategies to overcome resistance of glioblastoma to temozolomide.Semantic proximity Read ↗

Temozolomide resistance in glioblastoma multiformeSemantic proximity Read ↗

Recurrent Glioblastomas Reveal Molecular Subtypes Associated with Mechanistic Implications of Drug-ResistanceSemantic proximity Read ↗

MGMT Promoter Methylation Status Can Predict the Incidence and Outcome of Pseudoprogression After Concomitant Radiochemotherapy in Newly Diagnosed Glioblastoma PatientsSemantic proximity Read ↗

Inhibition of DNA-repair genes Ercc1 and Mgmt enhances temozolomide efficacy in gliomas treatment: a pre-clinical studySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.